Original Research Article
Year: 2022 | Month: November | Volume: 9 | Issue: 11 | Pages: 392-398
DOI: https://doi.org/10.52403/ijrr.20221153
A Comparative Study of Therapeutic Efficacy of BCG Immunotherapy (50 Cases) and Vitamin D (50 Cases) in Cutaneous Warts (Total 100 Cases)
Nidhi Patel1, Deval Vora2, Khyati Sidapara3, Prachi Mehta4, Sumana M5
1,3,4Third Year Resident, Department of Skin V.D and Leprosy, Shri M.P. Shah Government Medical College, Jamnagar-361008
2Professor and head of department, Department of Skin V.D and Leprosy, Shri M.P. Shah Government Medical College, Jamnagar-361008
5First Year Resident, Department of Skin V.D and Leprosy, Shri M.P. Shah Government Medical College, Jamnagar-361008
Corresponding Author: Nidhi Patel
ABSTRACT
Background: Human papilloma virus infects the epithelium of skin or mucosal cells to cause warts. Most of the current therapeutic modalities are ablative, act only on targeted lesions, and lack a well-defined treatment endpoint. These procedures have high recurrence rates, side effects and are not effective over distant warts. Intralesional immunotherapy acts on cell mediated immunity to treat local as well as distant lesions.
Aims and objectives: To evaluate the efficacy and safety of intralesional BCG and intralesional VITAMIN D and to compare efficacy and safety of intralesional BCG and intralesional VITAMIN D in the treatment of patients with cutaneous warts.
Materials and Methods: This study included 100 adult patients with single or multiple warts of different size, number and duration with or without distance warts. Each patient was randomly assigned into Group 1 (BCG : 0.1mL of 1mg/mL) and Group 2 (vitamin D3 : 0.2mL of 15mg/mL). One or two warts were injected per session at interval of 21 days for three sessions. Response was assessed. Adverse effects were noted. Cases were further followed up after 3 months without any treatment to assess for any recurrences. In both the groups, standard medical treatment will be also given. Standard digital photographs were taken at each visit to support the data.
Results: The BCG group had the maximum patients with complete response (36 of 50, 72%) followed by VITAMIN D group (24 of 50, 48%). No major adverse drug reactions were reported in any of the group.
Limitations: Small sample size and absence of control group were the main limitations of our study.
Conclusion: Immunotherapy offers a safe, effective and affordable approach in the patients with multiple cutaneous viral warts with lesser side effects and recurrence rate.
Keywords: BCG, VITAMIN D, WARTS
[PDF Full Text]